HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hydroxyapatite coating does not improve uncemented stem survival after total hip arthroplasty!

AbstractBACKGROUND AND PURPOSE:
It is still being debated whether HA coating of uncemented stems used in total hip arthroplasty (THA) improves implant survival. We therefore investigated different uncemented stem brands, with and without HA coating, regarding early and long-term survival.
PATIENTS AND METHODS:
We identified 152,410 THA procedures using uncemented stems that were performed between 1995 and 2011 and registered in the Nordic Arthroplasty Register Association (NARA) database. We excluded 19,446 procedures that used stem brands less than 500 times in each country, procedures performed due to diagnoses other than osteoarthritis or pediatric hip disease, and procedures with missing information on the type of coating. 22 stem brands remained (which were used in 116,069 procedures) for analysis of revision of any component. 79,192 procedures from Denmark, Norway, and Sweden were analyzed for the endpoint stem revision. Unadjusted survival rates were calculated according to Kaplan-Meier, and Cox proportional hazards models were fitted in order to calculate hazard ratios (HRs) for the risk of revision with 95% confidence intervals (CIs).
RESULTS:
Unadjusted 10-year survival with the endpoint revision of any component for any reason was 92.1% (CI: 91.8-92.4). Unadjusted 10-year survival with the endpoint stem revision due to aseptic loosening varied between the stem brands investigated and ranged from 96.7% (CI: 94.4-99.0) to 99.9% (CI: 99.6-100). Of the stem brands with the best survival, stems with and without HA coating were found. The presence of HA coating was not associated with statistically significant effects on the adjusted risk of stem revision due to aseptic loosening, with an HR of 0.8 (CI: 0.5-1.3; p = 0.4). The adjusted risk of revision due to infection was similar in the groups of THAs using HA-coated and non-HA-coated stems, with an HR of 0.9 (CI: 0.8-1.1; p = 0.6) for the presence of HA coating. The commonly used Bimetric stem (n = 25,329) was available both with and without HA coating, and the adjusted risk of stem revision due to aseptic loosening was similar for the 2 variants, with an HR of 0.9 (CI: 0.5-1.4; p = 0.5) for the HA-coated Bimetric stem.
INTERPRETATION:
Uncemented HA-coated stems had similar results to those of uncemented stems with porous coating or rough sand-blasted stems. The use of HA coating on stems available both with and without this surface treatment had no clinically relevant effect on their outcome, and we thus question whether HA coating adds any value to well-functioning stem designs.
AuthorsNils P Hailer, Stergios Lazarinis, Keijo T Mäkelä, Antti Eskelinen, Anne M Fenstad, Geir Hallan, Leif Havelin, Søren Overgaard, Alma B Pedersen, Frank Mehnert, Johan Kärrholm
JournalActa orthopaedica (Acta Orthop) Vol. 86 Issue 1 Pg. 18-25 (Feb 2015) ISSN: 1745-3682 [Electronic] Sweden
PMID25175664 (Publication Type: Journal Article)
Chemical References
  • Coated Materials, Biocompatible
  • Hydroxyapatites
Topics
  • Aged
  • Arthroplasty, Replacement, Hip (methods)
  • Cementation (methods)
  • Coated Materials, Biocompatible (therapeutic use)
  • Cohort Studies
  • Denmark
  • Female
  • Hip Dislocation, Congenital (surgery)
  • Humans
  • Hydroxyapatites (therapeutic use)
  • Kaplan-Meier Estimate
  • Legg-Calve-Perthes Disease (surgery)
  • Male
  • Middle Aged
  • Norway
  • Osteoarthritis, Hip (surgery)
  • Proportional Hazards Models
  • Prosthesis Design
  • Prosthesis Failure
  • Prosthesis-Related Infections
  • Registries
  • Reoperation (statistics & numerical data)
  • Sweden
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: